Pyoderma gangrenosum: an expert commentary

References

• Brunsting LA, Goeckerman WH, O’Leary PA. Pyoderma gangrenosum: clinical and experimental observations in five cases occurring in adults. Arch. Dermatol. Syphilol.22, 655–680 (1930).
   Google Scholar
• Adachi Y, Kindzelskii AL, Cookingham G et al. Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J. Invest. Dermatol.111, 259–268 (1998).
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Kyoko H, Hachiya M et al. Pyoderma gangrenosum of the skin and respiratory tract in a 5 year-old girl. Eur. J. Pediatr.162, 344–345 (2003).
   PubMedGoogle Scholar
• Powell FC, Collins S. Pyoderma gangrenosum. Clin. Dermatol.18, 283–293 (2000).
   PubMed Web of Science ®Google Scholar
• Vidal D, Puig L, Gilaberte M, Alomar A. Review of 26 cases of classical pyoderma gangrenosum: clinical and therapeutic features. J. Dermatol. Treatment.15, 146–152 (2004).
   PubMedGoogle Scholar
• Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB, White WL, Callen JP. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine79, 37–46 (2000).
   PubMed Web of Science ®Google Scholar
• Charles CA, Bialy TL, Falabella AF, Eaglestein WH, Kerdel FA, Kirsner RS. Poor prognosis of arthritis-associated pyoderma gangrenosum. Arch. Dermatol.140, 861–864 (2004).
   PubMedGoogle Scholar
• Shankar S, Sterling JC, Rytina E. Pustular pyoderma gangrenosum. Clin. Exp. Dermatol.28, 600–603 (2003).
   PubMed Web of Science ®Google Scholar
• Walling HW, Snipes CJ, Gerami P, Piette WW. The relationship between neutrophilic dermatosis of the dorsal hands and sweet syndrome: report of 9 cases and comparison to atypical pyoderma gangrenosum. Arch. Dermatol.142, 57–63 (2006).
   PubMedGoogle Scholar
• Louis DS, Jebson PJ. Mimickers of hand infections. Hand Clinics4, 519–529 (1998).
   Google Scholar
• Huish SB, de La Paz EM, Ellis PR, Stern PJ. Pyoderma gangrenosum of the hand: a case series and review of the literature. J. Hand Surg. Am.26, 679–685 (2001).
   PubMedGoogle Scholar
• Isomura I, Miyawaki S, Morita A. Pyoderma gangrenosum associated with nasal septal perforation, orophayngeal ulders and IgA paraproteinemia. J. Dermatol.32, 193–198 (2005).
   PubMedGoogle Scholar
• Jackson JM, Callen JP. Pyoderma gangrenosum and IgA myeloma. J. Cutan. Med. Surg.2, 100–103 (1997).
   Google Scholar
• Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA284, 1546–1548 (2000).
   PubMed Web of Science ®Google Scholar
• Lally A, Hollowood K, Bunker CB, Turner R. Penile pyoderma gangrenosum treated with topical tacrolimus. Arch. Dermatol.141, 1175–1176 (2005).
   PubMedGoogle Scholar
• Hernandez-Martin A, Arias-Paloma D, Hermida G et al. Oral pyoderma gangrenosum. Br. J. Dermatol.149, 663–664 (2003).
   PubMedGoogle Scholar
• Setterfield JF, Shirlaw PJ, Challacombe SJ, Black MM. Pyoderma gangrenosum associated with severe oropharyngeal involvement and IgA paraproteinemia. Br. J. Dermatol.144, 393–396 (2001).
   PubMedGoogle Scholar
• Lachapelle JM, Marot L, Jablonska S. Superficial granulomatous pyoderma gangrenosum of the face successfully treated by cyclopsorin: a long-term follow-up. Dermatology202, 155–157 (2001).
   PubMed Web of Science ®Google Scholar
• Yoshida C, Kojima H, Shigaki T et al. Association of pyoderma gangrenosum and sterile osteomyelitis in a patient having myelodysplastic syndrome. Eur. J. Heamatol.72, 149–153 (2004).
   PubMedGoogle Scholar
• Nurre LD, Rabalais GP, Callen JP. Neutrophilic dermatosis-associated sterile chronic multifocal osteomyelitis in pediatric patients: case report and review. Ped. Dermatol.16, 214–216 (1999).
   PubMedGoogle Scholar
• Wilson DM, John GR, Callen JP. Peripheral ulcerative keratitis- an extracutaneous neutrophilic disorder: report of a patient with rheumatoid arthritis, pustular vasculitis, pyoderma gangrenosum, and Sweet’s syndrome with an excellent response to cyclosporine therapy. J. Am. Acad. Dermatol.40, 331–334 (1999).
   PubMedGoogle Scholar
• Brown TS, Marshall GS, Callen JP. Cavitating pulmonary infiltrate in an adolescent with pyoderma gangrenosum: a rarely recognized extracutaneous manifestation of a neutrophilic dermatosis. J. Am. Acad. Dermatol.43, 108–112 (2000).
   PubMedGoogle Scholar
• Vadillo M, Jucgla A, Podzamczer D, Rufi G, Domingo A. Pyoderma gangrenosum with liver, spleen, and bone involvement in a patient with chronic myelomonocytic leukemia. Br. J. Dermatol.141, 541–543 (1999).
   PubMed Web of Science ®Google Scholar
• Muster AJ, Bharati S, Herman JJ, Esterly NB, Gonzales-Crussi F, Holbrook KA. Fatal cardiovascular disease and cutis laxa following acute febrile neutrophilic dermatosis. J. Pediatr.102, 243–248 (1983).
   PubMedGoogle Scholar
• Marie I, Levesque H, Joly P et al. Neutrophilic myositis as an extracutaneous manifestation of neutrophilic dermatosis. J. Am. Acad. Dermatol.44(1), 137–139 (2001).
   PubMedGoogle Scholar
• Vignon-Pennamen MD. The extracutaneous involvement in the neutrophilic dermatoses. Clin. Dermatol.18(3), 339–347 (2000).
   PubMedGoogle Scholar
• Trent JT, Kirsner RS. Diagnosing pyoderma gangrenosum. Adv. Skin Wound Care14, 151–153 (2001).
   PubMedGoogle Scholar
• Yang CC, Hsieh FS, Lee JY. Pyoderma gangrenosum complicated by ecthyma gangrenosum. Br. J. Dermatol.150, 1025–1026 (2004).
   PubMed Web of Science ®Google Scholar
• Byrd DR, El-Azhary RA, Gibson LE, Roberts GD. Sporotrichosis masquerading as pyoderma gangrenosum: case report and review of 19 cases of sporotrichosis. J. Eur. Acad. Dermatol. Venereol.15, 581–584 (2001).
   PubMed Web of Science ®Google Scholar
• Laochumroonvorapong P, DiCostanzo DR, Wu H, Srinivasan K, Abusamieh M, Levy H. Disseminated Histoplasmosis presenting as pyoderma gangrenosum-like lesions in a patient with acquired immunodeficiency syndrome. Int. J. Dermatol.40, 518–521 (2001).
   PubMedGoogle Scholar
• Schmid MH, Hary C, Marstaller, B, Konz B, Wendtner CM. Pyoderma gangrensoum associated with secondary antiphospholipid syndrome. Eur. J. Dermatol.1, 45–47 (1998).
   Google Scholar
• Smith JB, Shenefelt PD, Soto O, Valeriano J. Pyoderma gangrenosum in a patient with cryoglobulinemia and hepatitis C successfully treated with interferon α. J. Am. Acad. Dermatol.34, 901–903 (1996).
   PubMedGoogle Scholar
• Barrio VR, Sanfilippo AM, Malone JC, Callen JP. Nonhealing ulcer secondary to factor V Leiden mutation and cryofibrinogenemia. J. Am. Acad. Dermatol.51(5 Suppl.), S194–S196 (2004).
   Google Scholar
• Oh CC, McKenna DB, McLaren KM, Tidman MJ. Factitious panniculitis masquerading as pyoderma gangrenosum. Clin. Exp. Dermatol.30, 253–255 (2005).
   PubMedGoogle Scholar
• Weenig RH, Davis MD, Dahl PR, Su WP. Skin ulcers misdiagnosed as pyoderma gangrenosum. N. Engl. J. Med.347(18), 1412–1418 (2002).
   PubMed Web of Science ®Google Scholar
• Su WPD, Davis MD, Weenig RH, Powell FC, Perry HO. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int.J. Dermatol.43, 790–800 (2004).
   PubMed Web of Science ®Google Scholar
• Malone JC, Slone SP, Wills-Frank LA et al. Vascular inflammation (vasculitis) in sweet syndrome: a clinicopathologic study of 28 biopsy specimens from 21 patients. Arch. Dermatol.138(3), 345–349 (2002).
   PubMedGoogle Scholar
• Farina MC, Requena L, Domine M, Soriano ML, Estevez L, Barat A. Histopathology of cutaneous reaction to granulocyte colony-stimulating factor: another pseudomalignancy. J. Cut. Path.25(10), 559–562 (1998).
   PubMed Web of Science ®Google Scholar
• Brown TS, Callen JP. Atypical presentation of herpes simplex virus in a patient with chronic lymphocytic leukemia. Cutis64(2), 123–125 (1999).
   PubMedGoogle Scholar
• Gettler S, Rothe M, Grin C, Grant-Kels J. Optimal treatment of pyoderma gangrenosum. Am. J. Clin. Dermatol.4, 597–608 (2003).
   PubMed Web of Science ®Google Scholar
• Powell FC, O’Kane M. Management of pyoderma gangrenosum. Dermatol. Clin.20, 347–55 (2002).
   PubMed Web of Science ®Google Scholar
• de ImusG, Golomb C, Wilkel C, Tsoukas M, Nowak M, Falanga V. Accelerated healing of pyoderma gangrenosum treated with bioengineered skin and concomitant immunosuppression. J. Am. Acad. Dermatol.44, 61–66 (2001).
   PubMed Web of Science ®Google Scholar
• Chiba T, Isomura I, Suzuki A, Morita A. Topical tacrolimus therapy for pyoderma gangrenosum. J. Dermatol.32, 199–203 (2005).
   PubMedGoogle Scholar
• Vidal D, Alomar A. Successful treatment of peristomal pyoderma gangrenosum using topical tacrolimus. Br. J. Dermatol.150, 387–388 (2004).
   PubMed Web of Science ®Google Scholar
• Nybaek H, Olsen AG, Karlsmark T, Jemec GB. Topical therapy for peristomal pyoderma gangrenosum. J. Cutan. Med. Surg.8, 220–223 (2004).
   PubMedGoogle Scholar
• Patel GK, Thodes JR, Evans B, Holt PJ. Successful treatment of pyoderma gangrenosum with topical 0.5% nicotine cream. J. Dermatological. Treat.15, 122–125 (2004).
   PubMedGoogle Scholar
• Langenbach N, Goetz A, Hohenleutner U, Landthaler M. Effectiveness of 4% disodium cromoglycate in the treatment of disseminated pyoderma gangrenosum. Acta Derm. Venereol.76, 501–502 (1996).
   PubMedGoogle Scholar
• Zakhireh M, Rockwell WB, Fryer RH. Stabilization of pyoderma gangrenosum ulcer with oral cyclosporine prior to skin grafting. Plastic Recon. Surg.113, 1417–1420 (2004).
   PubMed Web of Science ®Google Scholar
• Patrone P, Bragadin G, De Francesco V, Frattasio A, Stinco G. Pyoderma gangrenosum of the scalp treated with cyclopsorine A. Int. J. Dermatol.41, 916–918 (2002).
   PubMedGoogle Scholar
• Schofer H, Baur S. Successful treatment of postoperative pyoderma gangrenosum with cyclosporin. J. Eur. Acad. Dermatol. Venereol.16, 148–151 (2002).
   PubMed Web of Science ®Google Scholar
• Daniels NH, Callen JP. Mycophenolate mofetil is an effective treatment for peristomal pyoderma gangrenosum. Arch. Dermatol.140, 1427–1429 (2004).
   PubMed Web of Science ®Google Scholar
• Lee MR, Cooper AJ. Mycophenolate mofetil in pyoderma gangrenosum. J. Dermatol. Treat.15, 303–307 (2004).
   PubMedGoogle Scholar
• Nousari HC, Lynch W, Anhalt GJ, Petri M. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch. Dermatol.134, 1509–1511 (1998).
   PubMed Web of Science ®Google Scholar
• Teitel AD. Treatment of pyoderma gangrenosum with methotrexate. Cutis57, 326–328 (1996).
   PubMedGoogle Scholar
• Burruss JB, Farmer ER, Callen JP. Chlorambucil is an effective corticosteroid-sparing agent for recalcitrant pyoderma gangrenosum. J. Am. Acad. Dermatol.5, 720–724 (1996).
   Google Scholar
• Federman GL, Federman DG. Recalcitrant pyoderma gangrenosum treated with thalidomide. Mayo Clin. Proc.75, 842–844 (2000).
   PubMed Web of Science ®Google Scholar
• Kontochristopoulos GJ, Stavropoulos PG, Gregoriou S, Zakopoulou N. Treatment of pyoderma gangrenosum with low-dose colchicine. Dermatology209, 233–236 (2004).
   PubMedGoogle Scholar
• Reynoso-von Drateln C, Perla-Navarro AV, Gamez-Nava JI, Gonzalez-Lopez L, Galvan-Billegas F, Ramos-Remus C. Intravenous cyclophosphamide pulses in pyoderma gangrenosum: an open trial. J. Rheumatol.24, 689–693 (1997).
   PubMedGoogle Scholar
• Fox LP, Pandya AG. Pulse intravenous cyclophosphamide therapy for dermatologic disorders. Dermatol. Clin.18(3), 459–473 (2000).
   PubMedGoogle Scholar
• Shenefelt PD. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen. Cutis57, 315–319 (1996).
   PubMed Web of Science ®Google Scholar
• Mcgowan JW, Johnson CA, Lynn A. Treatment of pyoderma gangrenosum with etanercept. J. Drugs Dermatol.3, 441–444 (2004).
   PubMedGoogle Scholar
• Jenne L, Sauter B, Thurmann P, Hertl M, Schuler G. Successful treatment of therapy-resistant chronic vegetating pyoderma gangrenosum with infliximab. Br. J. Dermatol.150, 380–382 (2004).
   PubMed Web of Science ®Google Scholar
• Mimouni D, Anhalt GJ, Kouba DJ, Nourari HC. Infliximab for peristomal pyoderma gangrenosum. Br. J. Dermatol.148, 813–816 (2003).
   PubMed Web of Science ®Google Scholar
• Stichweh DS, Punaro M, Pascual V. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatr. Dermatol.22, 262–265 (2005).
   PubMed Web of Science ®Google Scholar
• Bens G, Laharie D, Beylot-Barry M et al. Successful treatment with infliximab and methotrexate of pyostomatitis vegetans associated with Crohn’s disease. Br. J. Dermatol.149(1), 181–184 (2003).
   PubMed Web of Science ®Google Scholar
• Brooklyn TN, Dunnill GS, Shetty A et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double-blind placebo-controlled trial. Gut55(4), 505–509 (2006).
   PubMed Web of Science ®Google Scholar
• Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br. J. Dermatol.152, 1059–1061 (2005).
   PubMed Web of Science ®Google Scholar
• Hagman JH, Carrozzo AM, Campione E, Romanelli P, Chimenti S. The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum. J. Dermatol. Treat.12, 19–22 (2001).
   PubMed Web of Science ®Google Scholar
• Dirschka T, Kastner U, Behrens S, Altmeyer P. Successful treatment of pyoderma gangrenosum with intravenous human immunoglobulin. J. Am. Acad. Dermatol.39, 789–790 (1998).
   PubMedGoogle Scholar
• Kiran RP, O’Brien-Ermlich B, Achkar JP, Fazio VW, Delaney CP. Management of peristomal pyoderma gangrenosum. Dis. Col. Rectum48(7), 1397–1403 (2005).
   PubMed Web of Science ®Google Scholar